Elicio Therapeutics, Inc.
ELTX evidence brief
What we can confirm
- BioSniper Score:
- 5.8 / 10
- Market Cap:
- $53.9M
- Lead Asset:
- eli-002 (Phase 2)
What it means
What to watch
Prepared research question
What matters most for ELTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ELTX
Elicio Therapeutics, Inc. (ELTX) is a clinical-stage biotechnology company developing immunotherapies targeting KRAS/NRAS-mutated cancers, with a lead candidate ELI-002 7P in Phase 2/3 development for pancreatic cancer. As of June 30, 2026, the company reported $23.5M in cash and equivalents and a net loss of $8.2M [sec].
Key risk: Cash runway risk
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$53.9M
Cash Runway
—
Lead Asset
eli-002 (Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 3 clinical trials for Elicio Therapeutics, Inc..
Similar companies
Elicio Therapeutics, Inc. (ELTX) is a clinical-stage biotechnology company developing immunotherapies targeting KRAS/NRAS-mutated cancers, with a lead candidate ELI-002 7P in Phase 2/3 development for pancreatic cancer. As of June 30, 2026, the company reported $23.5M in cash and equivalents and a net loss of $8.2M [sec].
- Lead product candidate ELI-002 7P is a 7-peptide immunotherapy targeting KRAS/NRAS mutations in pancreatic ductal adenocarcinoma and other solid tumors [sec_mda · as of 2026-08-13].
- Phase 2 AMPLIFY-7P trial did not meet its primary endpoint; the company continues to evaluate pre-specified subgroups to refine Phase 3 strategy [news · published 2026-08-13].
- A Phase 1 combination study of ELI-002 7P plus a RAS small molecule inhibitor with or without an anti-PD-1 inhibitor is anticipated to initiate in Q4 2026 [sec_mda · as of 2026-08-13].
- Cash and equivalents were $23.5M as of June 30, 2026, with a net loss of $8.2M and shareholders' equity of $7.9M [sec].
- The company has expressed substantial doubt about its ability to continue as a going concern, with cash runway expected into Q1 2027 based on current operating plan [sec_mda · as of 2026-08-13].
What works
- ELI-002 7P has shown multiple complete responses in prior studies, supporting a planned Phase 1 combination study [news · published 2026-08-13].
- The company has raised approximately $227.5M in aggregate net proceeds from equity and debt financings since inception [sec_mda · as of 2026-05-11].
- Elicio is actively refining its Phase 3 development strategy for ELI-002 7P based on pre-specified subgroup analyses, including the R0 resected population [news · published 2026-08-13].
What to weigh
- Phase 2 AMPLIFY-7P trial did not meet its primary endpoint, creating uncertainty for the program [news · published 2026-08-13].
- The company has expressed substantial doubt about its ability to continue as a going concern, with cash runway only into Q1 2027 [sec_mda · as of 2026-08-13].
- Elicio has had significant operating losses since inception, with a net loss of $8.2M in Q2 2026 alone [sec].
- The company expects expenses to increase significantly as it advances development and seeks regulatory approvals, while net losses may fluctuate [sec_mda · as of 2026-08-13].
From the filings
Quoted directly from source documents.
Phase 2 AMPLIFY-7P trial did not meet its primary endpoint
“While Phase 2 AMPLIFY-7P trial did not meet its primary endpoint, Elicio continues to evaluate pre-specified subgroups”
News · August 13, 2026
Cash runway into Q1 2027
“we believe that our cash on hand will enable us to fund our operations into the first quarter of 2027 based on our current financial operating plan”
SEC MD&A · August 13, 2026
Substantial doubt about going concern
“We are currently facing substantial doubt about our ability to continue as a going concern, given our cash position and cash runway”
SEC MD&A · August 13, 2026
Phase 1 combination study planned Q4 2026
“We anticipate the Phase 1 study to initiate in the fourth quarter of 2026”
SEC MD&A · August 13, 2026
Catalyst timeline
- 2021-10-04 · Phase 1 Start — First in Human Phase 1 Trial of ELI-002 Immunotherapy for KRAS-mutated pancreatic cancer and other solid tumors.
- 2023-04-14 · Phase 2 Start — First in Human Phase 1/2 Trial of ELI-002 7P Immunotherapy for KRAS/NRAS-mutated pancreatic cancer and other solid tumors.
Risks & what to watch (4)›
Key risks
- Cash runway risk — Cash on hand expected to fund operations only into Q1 2027; company has expressed substantial doubt about going concern [sec_mda · as of 2026-08-13].
- Phase 2 miss — Phase 2 AMPLIFY-7P trial did not meet its primary endpoint, jeopardizing the lead program [news · published 2026-08-13].
- Continued net losses — Company has had significant operating losses since inception; net loss was $8.2M in Q2 2026 [sec].
- Regulatory and development uncertainty — Forward-looking statements note risks in clinical trial outcomes, regulatory approvals, and commercialization [sec · filed 2026-04-29].
What to watch
- Initiation of Phase 1 combination study of ELI-002 7P plus RAS small molecule inhibitor, anticipated Q4 2026 [sec_mda · as of 2026-08-13].
- Potential study readouts from the Phase 1 combination study, expected 3-6 months after start [sec_mda · as of 2026-08-13].
- Further details on Phase 3 development strategy for ELI-002 7P based on subgroup analyses [news · published 2026-08-13].
- Cash position and any additional financing activities given the limited runway into Q1 2027 [sec_mda · as of 2026-08-13].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 11, 2026 · How we verify sources →
Run Elicio Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Elicio Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 2.95 · 0% dilution
Lead: Phase 1/Phase 2
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
47
Total value held
$28.0M
| Holder | Shares | Value |
|---|---|---|
| knoll capital management, llc | 630,915 | $6.7M |
| vanguard capital management llc | 518,638 | $5.5M |
| balyasny asset management l.p. | 244,814 | $2.6M |
| geode capital management, llc | 135,164 | $1.4M |
| renaissance technologies llc | 121,631 | $1.3M |
| millennium management llc | 92,762 | $992K |
| marshall wace, llp | 74,512 | $797K |
| susquehanna international group, llp | 70,804 | $757K |
| vanguard fiduciary trust co | 69,189 | $740K |
| northern trust corp | 59,734 | $639K |
Showing top 10 of 47 institutional holders of Elicio Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 12.9%
- Days to cover
- 13.2
- Shares short
- 1,658,153
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ELTX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Elicio Therapeutics, Inc.?
Elicio Therapeutics, Inc. (ELTX) is a clinical-stage biotechnology company developing immunotherapies targeting KRAS/NRAS-mutated cancers, with a lead candidate ELI-002 7P in Phase 2/3 development for pancreatic cancer. As of June 30, 2026, the company reported $23.5M in cash and equivalents and a net loss of $8.2M [sec].
What is Elicio Therapeutics, Inc.'s lead drug candidate?
Elicio Therapeutics, Inc.'s most advanced tracked candidate is eli-002 (Phase 2) for Minimal Residual Disease.
Who is the CEO of Elicio Therapeutics, Inc.?
Mr. Robert T. Connelly is the chief executive officer of Elicio Therapeutics, Inc. (ELTX).
Where is Elicio Therapeutics, Inc. headquartered?
Elicio Therapeutics, Inc. (ELTX) is headquartered in Boston, MA, United States.
What therapeutic areas does Elicio Therapeutics, Inc. focus on?
Elicio Therapeutics, Inc. develops therapies across Oncology, Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.